Kymera Therapeutics (NASDAQ: KYMR) director details option exercises, stock sales

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. director reports option exercises and stock sales. On 12/17/2025, the reporting person, a director of Kymera Therapeutics (KYMR), exercised stock options and sold common shares under a pre-arranged Rule 10b5-1 trading plan adopted on September 17, 2025.

The director exercised options for 12,563 shares at $49.10, 12,000 shares at $27.67, and 3,000 shares at $31.20, acquiring a total of 27,563 common shares. On the same date, they sold 14,505 shares at a weighted average price of $81.557, 7,959 shares at $82.3422, 4,099 shares at $83.4507, and 1,000 shares at $84.07, leaving 0 directly owned common shares.

Following these transactions, the director continued to hold stock options, including 7,500 options with a $49.10 exercise price expiring on June 15, 2031, and 13,000 options with a $31.20 exercise price expiring on June 18, 2034. All underlying option shares were reported as fully vested and exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Esposito Pamela

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/17/2025		M(1)		12,563	A	$49.1	12,563	D
Common Stock	12/17/2025		M(1)		12,000	A	$27.67	24,563	D
Common Stock	12/17/2025		M(1)		3,000	A	$31.2	27,563	D
Common Stock	12/17/2025		S(1)		14,505	D	$81.557(2)	13,058	D
Common Stock	12/17/2025		S(1)		7,959	D	$82.3422(3)	5,099	D
Common Stock	12/17/2025		S(1)		4,099	D	$83.4507(4)	1,000	D
Common Stock	12/17/2025		S(1)		1,000	D	$84.07(5)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$49.1	12/17/2025		M(1)			12,563	(6)	06/15/2031	Common Stock	12,563	$0	7,500	D
Stock Option (Right to Buy)	$27.67	12/17/2025		M(1)			12,000	(6)	06/15/2033	Common Stock	12,000	$0	0	D
Stock Option (Right to Buy)	$31.2	12/17/2025		M(1)			3,000	(6)	06/18/2034	Common Stock	3,000	$0	13,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.99 to $81.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.99 to $83.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.99 to $84.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

6. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kymera Therapeutics (KYMR) report?

The filing reports that a director of Kymera Therapeutics, Inc. exercised stock options and sold the resulting common shares on 12/17/2025, ending the day with 0 directly owned common shares.

How many Kymera Therapeutics (KYMR) shares did the director acquire and sell?

The director exercised options to acquire a total of 27,563 Kymera common shares and sold 27,563 shares on 12/17/2025 in multiple transactions at different weighted average prices.

At what prices were the Kymera Therapeutics (KYMR) options exercised and shares sold?

The options were exercised at $49.10, $27.67, and $31.20 per share. The resulting shares were sold at weighted average prices of $81.557, $82.3422, $83.4507, and $84.07 per share.

Was the Kymera Therapeutics (KYMR) insider trading activity under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 that was adopted by the reporting person.

Does the Kymera Therapeutics (KYMR) director still hold stock options after these transactions?

After the reported transactions, the director held 7,500 stock options with a $49.10 exercise price expiring on June 15, 2031, and 13,000 stock options with a $31.20 exercise price expiring on June 18, 2034.

What do the weighted average prices mean in the Kymera Therapeutics (KYMR) Form 4?

The filing explains that the reported sale prices are weighted average prices for multiple trades in price ranges (for example, from $80.99 to $81.98), and that detailed trade-by-trade information is available upon request.